Autopsy report · NCT02095353
Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
Cause of deathFunding or business, also safety
“FDA safety concerns with repeated use of gadolinium-based contrast; subjects received additional dose of contrast with no direct clinical benefit”
Life of this trial
- Registered 6 months before it started.
- Ran for about 2 years 6 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Sponsor
- University of Nebraska
- Sponsor type
- University, hospital or other
- Conditions
- Central Nervous System Neoplasms
- Participants
- 6
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.